Skip to Content
MilliporeSigma
  • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

European journal of internal medicine (2015-05-15)
Matthieu Groh, Christian Pagnoux, Chiara Baldini, Elisabeth Bel, Paolo Bottero, Vincent Cottin, Klaus Dalhoff, Bertrand Dunogué, Wolfgang Gross, Julia Holle, Marc Humbert, David Jayne, J Charles Jennette, Romain Lazor, Alfred Mahr, Peter A Merkel, Luc Mouthon, Renato Alberto Sinico, Ulrich Specks, Augusto Vaglio, Michael E Wechsler, Jean-François Cordier, Loïc Guillevin
ABSTRACT

To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Vinylene carbonate, contains ≤2% BHT as stabilizer, 97%